Abstract |
Twenty-three patients (12 females, 11 males) with malignant non-Hodgkin's lymphoma were treated with oral trofosfamide 50 mg t.i.d. Median age was 72 years. Fifteen patients had low-grade and 8 had high-grade lymphomas. Twenty-one patients had stage III and IV disease. Seven patients had WHO performance status of 3-4. The overall response rate was 61% (CR 22%, PR 39%) and the median duration of response 4 months (range 1.5-15+). The main side-effect was bone marrow depression and 7 patients experienced grade II or III hematological toxicity. No gastrointestinal or renal toxicity, no hair loss and no neurotoxicity were observed. The subjective tolerance was good.
|
Authors | E Wist, T Risberg |
Journal | Acta oncologica (Stockholm, Sweden)
(Acta Oncol)
Vol. 30
Issue 7
Pg. 819-21
( 1991)
ISSN: 0284-186X [Print] England |
PMID | 1764273
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Cyclophosphamide
- trofosfamide
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Cyclophosphamide
(adverse effects, analogs & derivatives, therapeutic use)
- Drug Evaluation
- Female
- Hodgkin Disease
(drug therapy)
- Humans
- Lymphoma, Non-Hodgkin
(drug therapy)
- Male
- Middle Aged
|